Immunovant (NASDAQ:IMVT – Get Free Report) issued its earnings results on Monday. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.27, Zacks reports. During the same period last year, the firm posted ($0.73) earnings per share.
Here are the key takeaways from Immunovant’s conference call:
- LISRAYA generated $31 million in net revenue during its first five weeks on the market, with hundreds of patients on paid treatment and broad prescriber interest. Roivant said pharmacy inventory contributed a quarter-end tailwind that may modestly reverse in the December quarter, and cautioned that it is too early to extrapolate launch trends.
- In difficult-to-treat rheumatoid arthritis, IMVT-1402 at 600 mg maintained ACR20 responses in 92.5% of patients at the end of the randomized-withdrawal period, versus about 75% on placebo; 300 mg performed similarly to placebo. The company reported no new safety signals, but FDA discussions on the next trial’s design and approval path are ongoing.
- Roivant highlighted positive non-infectious uveitis results: treatment failure occurred at about 12 weeks for placebo patients, while median treatment failure was not reached beyond 48 weeks for brepocitinib-treated patients. The company plans to file a supplemental application for the indication and sees it as a potential additional commercial opportunity.
- Mosliciguat’s PH-ILD study showed a reported 56% placebo-adjusted reduction in pulmonary vascular resistance and a statistically significant 35-meter improvement in six-minute walk distance. Its Phase III study is enrolling, and Roivant is evaluating additional pulmonary hypertension and lung-disease indications.
- Roivant said its cutaneous lupus erythematosus program had not succeeded and that it is unlikely to advance IMVT-1402 in Sjögren’s syndrome, citing competitor results and other field updates. It plans to complete the ongoing Sjögren’s study and assess the remaining data.
Immunovant Trading Up 3.7%
IMVT opened at $37.04 on Thursday. The business has a 50 day moving average of $32.83 and a 200-day moving average of $32.26. The stock has a market capitalization of $7.65 billion, a price-to-earnings ratio of -14.47 and a beta of 0.95. Immunovant has a 1-year low of $21.86 and a 1-year high of $45.42.
Analyst Ratings Changes
Get Our Latest Analysis on IMVT
Insider Buying and Selling at Immunovant
In related news, CEO Eric Venker sold 3,506 shares of the firm’s stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $34.11, for a total value of $119,589.66. Following the completion of the transaction, the chief executive officer directly owned 257,075 shares of the company’s stock, valued at $8,768,828.25. This trade represents a 1.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CTO Jay Stout sold 2,595 shares of Immunovant stock in a transaction on Wednesday, October 21st. The stock was sold at an average price of $28.94, for a total transaction of $75,099.30. Following the sale, the chief technology officer owned 198,937 shares in the company, valued at $5,757,236.78. This represents a 1.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 24,430 shares of company stock valued at $787,852 in the last quarter. 1.90% of the stock is currently owned by corporate insiders.
Immunovant Company Profile
Immunovant, Inc. is a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases. Its research focuses on inhibiting the neonatal Fc receptor (FcRn), a pathway involved in maintaining levels of disease-causing antibodies. The company’s investigational medicines include batoclimab and IMVT-1402, both designed to reduce circulating antibodies. Immunovant has studied or evaluated these candidates for conditions including myasthenia gravis, Graves’ disease and other autoimmune disorders.
See Also
- Five stocks we like better than Immunovant
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Immunovant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunovant and related companies with MarketBeat.com's FREE daily email newsletter.
